Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer

Journal: Cell

Published: 2018-06-14

DOI: 10.1016/j.cell.2018.04.034

Affiliations: 20

Authors: 20

Go to article
Institutions FC
Michigan Center for Translational Pathology (MCTP), U-M, United States of America (USA) 0.39
Department of Pathology, U-M, United States of America (USA) 0.12
Department of Internal Medicine, U-M, United States of America (USA) 0.08
Human Biology Division, FHCRC, United States of America (USA) 0.07
UCSF Department of Medicine (DOM), United States of America (USA) 0.06
Department of Medicine, UW, United States of America (USA) 0.03
Rogel Cancer Center, U-M, United States of America (USA) 0.03
Department of Oncology, WSU, United States of America (USA) 0.03
Barbara Ann Karmanos Cancer Institute, WSU, United States of America (USA) 0.03
ICR Division of Clinical Studies, United Kingdom (UK) 0.03
ICR Joint Department of Physics, United Kingdom (UK) 0.03
Department of Surgery, U-M, United States of America (USA) 0.02
University of Washington (UW), United States of America (USA) 0.02
VA Puget Sound Health Care System (VAPSHCS), United States of America (USA) 0.02
Clinical Research Division, FHCRC, United States of America (USA) 0.02
UCSF Helen Diller Family Comprehensive Cancer Center, United States of America (USA) 0.01
UCSF Department of Urology, United States of America (USA) 0.01
UCSF Department of Radiation Oncology, United States of America (USA) 0.01
Department of Urology, U-M, United States of America (USA) 0.01
University of Michigan (U-M), United States of America (USA) 0.01

Return